Loading, Please Wait...
WALTHAM, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its first quarter financial results ended March 31, 2019 and provided a business update.
“We believe 2019 will be a transformative year for Entasis as we advance our late-stage pipeline and expand our leadership team,” commented Manos Perros, President and Chief Executive Officer of Entasis Therapeutics. “To kick off the year, we recently initiated our global Phase 3 trial for ETX2514SUL against carbapenem-resistant Acinetobacter, for which we expect to have top line data in 2020. The initiation of this trial represents a major step forward for the Company. We also anticipate both the initiation of our Phase 3 trial for zoliflodacin for uncomplicated gonorrhea in collaboration with our partner Global Antibiotic Research and Development Partnership (GARDP), and Phase 1 data read-out of ETX0282CPDP, in mid-2019. With our first Phase 3 clinical trial underway, we have started to prepare our global commercialization strategy by bolstering our organization with the appointment of Eric Kimble as Chief Commercial Officer and Elizabeth Keiley as General Counsel. We look forward to leveraging their expertise as we advance towards commercialization.”
First Quarter and Recent Business Highlights
First Quarter Financial Results
The Company reported a net loss of $12.9 million for the quarter ended March 31, 2019, compared to a net loss of $10.7 million for the quarter ended March 31, 2018. The increase in net loss was primarily related to an increase in research and development expenses, partially offset by increases in other income.
Research and development expenses were $11.0 million for the quarter ended March 31, 2019, compared to $8.6 million for the quarter ended March 31, 2018. The increase in research and development expenses was primarily attributable to preclinical and clinical development expenses related to the advancement of our ETX2514SUL product candidate.
General and administrative expenses remained flat at $3.2 million for the quarter ended March 31, 2019 compared to the quarter ended March 31, 2018, as increased costs associated with additional headcount were offset by lower legal costs.
As of March 31, 2019, cash, cash equivalents and short-term investments were $74.6 million, compared to $85.1 million as of December 31, 2018.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding (i) the progress, timing and results of Entasis’ clinical trials; (ii) design of the Phase 3 clinical trial of ETX2514SUL, including plans to incorporate BIOFIRE Instruments and Pneumonia Panels into this trial; (iii) GARDP’s role in the Phase 3 clinical trial of zoliflodacin; and (iv) use of proceeds from the initial public offering. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis’ collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Many of these factors are beyond Entasis’ control. These and other risks and uncertainties are described more fully in the Entasis’ filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
The Ruth Group
(Financial Tables Follow)
|Entasis Therapeutics Holdings Inc.|
|Condensed Consolidated Statements of Operations|
|(in thousands, except share and per share data)|
|Three Months Ended March 31,|
|Research and development||$||11,002||$||8,550|
|General and administrative||3,189||3,218|
|Total operating expenses||14,191||11,768|
|Loss from operations||(14,191||)||(11,768||)|
|Total other income||1,321||1,101|
|Loss before income taxes||(12,870||)||(10,667||)|
|Provision for income taxes||71||-|
|Net loss per share—basic and diluted||$||(0.99||)||$||(844.01||)|
|Weighted average common stock outstanding—basic and diluted||13,126,595||12,639|
|Entasis Therapeutics Holdings Inc.|
|Condensed Consolidated Balance Sheets|
|March 31,||December 31,|
|Cash, cash equivalents and investments||$||74,555||$||85,092|
|Total stockholders' equity||70,574||82,883|
|Total liabilities and stockholders’ equity||$||81,267||$||89,274|